The Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fat-Soluble Vitamin Status and Supplementation in a Paediatric Cystic Fibrosis Cohort

The Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fat-Soluble Vitamin Status and Supplementation in a Paediatric Cystic Fibrosis Cohort | Authorea try { document.documentElement.classList.add('js'); } catch (e) { } var _gaq = _gaq || []; _gaq.push(['_setAccount', 'G-8VDV14Y67G']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); Skip to main content Preprints Collections Wiley Open Research IET Open Research Ecological Society of Japan All Collections About About Authorea FAQs Contact Us Quick Search anywhere Search for preprint articles, keywords, etc. Search Search ADVANCED SEARCH SCROLL This is a preprint and has not been peer reviewed. Data may be preliminary. 22 September 2025 V1 Latest version Share on The Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fat-Soluble Vitamin Status and Supplementation in a Paediatric Cystic Fibrosis Cohort Authors : Fern Kimber 0009-0000-9261-4293 and Darren Sills [email protected] Authors Info & Affiliations https://doi.org/10.22541/au.175855887.70376661/v1 182 views 122 downloads Contents Abstract Supplementary Material Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract Background : Children with Cystic fibrosis (CF) are at risk of fat-soluble vitamin deficiencies, studies have shown Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy to substantially improve nutritional status. This study aimed to investigate the effect of ETI on fat-soluble vitamin levels A, D and E, for children aged 6-16 years with CF. Method : We performed a retrospective cohort study of children with CF. Data collected included demographics, clinical characteristics, lung function, respiratory colonisation, serum vitamin A, D and E and vitamin supplementation dosages. Seven timepoints were decided for statistical analysis: T1-T3 – pre-ETI and T4-T7 – at 6 month intervals post-ETI. The significance of changes in vitamin levels and supplementation was assessed using a linear mixed-effects model. A p-value <0.05 was used to indicate significance. Results : Fifty-six children met the inclusion criteria, with 262, 257 and 252 complete observations for vitamins A, D and E, respectively. Median vitamin D levels increased from 77nmol/L to 85nmol/L (p<0.001). There was no significant increase in median vitamin A levels however post-ETI there was a significant association between supplementation dose and serum vitamin A levels (p=0.008). There were no significant changes in median vitamin E. Over the timepoints there was an increase in the proportion of patients receiving no vitamin supplementation. Conclusions : This study demonstrates ETI initiation increases vitamin D levels and lowers the requirement for fat-soluble vitamins supplementation. Whilst ETI did not cause significant increases in vitamin A and E, it appears there was a shift in vitamin A making supplementation more effective on ETI therapy. Supplementary Material File (impact of eti up to 2 years-2.docx) Download 1009.22 KB Information & Authors Information Version history V1 Version 1 22 September 2025 Copyright This work is licensed under a Non Exclusive No Reuse License. Keywords cystic fibrosis elexacaftor/tezacaftor/ivacaftor fat-soluble vitamins pancreatic insufficiency vitamin supplements Authors Affiliations Fern Kimber 0009-0000-9261-4293 University of Nottingham School of Medicine View all articles by this author Darren Sills [email protected] University of Nottingham School of Medicine View all articles by this author Metrics & Citations Metrics Article Usage 182 views 122 downloads .FvxKWukQNSOunydq8rnd { width: 100px; } Citations Download citation Fern Kimber, Darren Sills. The Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fat-Soluble Vitamin Status and Supplementation in a Paediatric Cystic Fibrosis Cohort. Authorea . 22 September 2025. DOI: https://doi.org/10.22541/au.175855887.70376661/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu . Format Please select one from the list RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks Direct import Tips for downloading citations document.getElementById('citMgrHelpLink').addEventListener('click', function() { popupHelp(this.href); return false; }); $(".js__slcInclude").on("change", function(e){ if ($(this).val() == 'refworks') $('#direct').prop("checked", false); $('#direct').prop("disabled", ($(this).val() == 'refworks')); }); View Options View options PDF View PDF Figures Tables Media Share Share Share article link Copy Link Copied! Copying failed. Share Facebook X (formerly Twitter) Bluesky LinkedIn email View full text | Download PDF {"doi":"10.22541/au.175855887.70376661/v1","type":"Article"} Now Reading: Share Figures Tables Close figure viewer Back to article Figure title goes here Change zoom level Go to figure location within the article Download figure Toggle share panel Toggle share panel Share Toggle information panel Toggle information panel Go to previous graphic Go to next graphic Go to previous table Go to next table All figures All tables View all material View all material xrefBack.goTo xrefBack.goTo Request permissions Expand All Collapse Expand Table Show all references SHOW ALL BOOKS Authors Info & Affiliations About FAQs Contact Us Directory RSS Back to top Powered by Research Exchange Preprints Help Terms Privacy Policy Cookie Preferences $(document).ready(() => setTimeout(() => { let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" ")); $.get("/resource/lodash?t="+_bnt); },4000)); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9ffb5092eb8e3fe2',t:'MTc3OTQ0NzYwMQ=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();